Beyond the Status Quo: Exploring the Future Impact of HBV Innovations
Webinar/Online
Monday, November 10, 2025 at 12:30pm ET - 2:00pm ET
Add this event to your calendar
Info
Topic
Join us for a live symposium to gain expert insight regarding limitations to current HBV therapy, emerging biomarkers, and therapies in the pipeline. Hear additional discussion about redefining goals of therapy with functional cure and learn about the clinical impact of emerging developments in care.
Credits Offered
This event offers
1.5 contact hours
to attendees.
Accreditation Info:
AANC.
Additional Information
Goal Statement
The goal of this activity is to improve learners’ knowledge and competence regarding limitations of current HBV therapy and the clinical impact of emerging developments in care.
Target Audience
This activity is intended for physicians, nurses, and pharmacists, including hepatologists and gastroenterologists, and other healthcare professionals involved in the care of patients living with chronic hepatitis B.
Learning Objectives
Upon completion of this event, participants should be able to:
- Evaluate the limitations of current antiviral therapy for HBV
- Outline the role of emerging biomarkers in evaluating disease status and treatment response for patients with HBV
- Examine the role of emerging agents for chronic HBV suppression and their potential to improve patient outcomes
Speakers
Section Head, Hepatology, Division of Gastroenterology and Hepatology
Director, Toronto Centre for Liver Disease, University Health Network
Senior Scientist, Toronto General Hospital Research Institute
Francis Family/Dr. Jenny Heathcote Chair in Liver Res
Professor of Medicine
Director, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Professor, Gastroenterology and Hepatology
Assistant Dean (Learning Experience)
Director, CUHK Medical Data Analytics Centre (MDAC)
Faculty of Medicine
The Chinese University of Hong Kong
Hong Kong, China